title: Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211At-mAb.
abstract: BACKGROUND
  Most carcinomas are prone to metastasize despite successful treatment of the primary tumor. One way to address this clinical challenge may be targeted therapy with α-emitting radionuclides such as astatine-211 (211At). Radioimmunotherapy utilizing α-particle emitting radionuclides is considered especially suitable for the treatment of small cell clusters and single cells, although lesions of different sizes may also be present in the patient. The aim of this study was primarily to evaluate the toxicity and secondarily in vivo efficacy of a 211At-labeled monoclonal antibody (mAb) directed against colon carcinoma with tumor diameters of approximately 10 mm.
  
  
  METHODS
  Eighteen rats with subperitoneal syngeneic colon carcinoma were allocated to three groups of six animals together with three healthy rats in each group. The groups were injected intravenously with either 150 μg of unlabeled mAbs (controls) or 2.5 or 5 MBq 211At-mAbs directed towards the Lewis Y antigen expressed on the cell membrane of several carcinomas. Tumor volume, body weight, and blood cell counts were monitored for 100 days after treatment.
  
  
  RESULTS
  Local tumors were non-palpable in five out of six rats after treatment with both activities of 211At-mAbs, compared to one out of six in the control group. At the study end, half of the animals in each group given 211At-BR96 and one animal in the control group were free from disease. Radioimmunotherapy resulted in dose-dependent, transient weight loss and myelotoxicity. Survival was significantly better in the groups receiving targeted alpha therapy than in those receiving unlabeled mAbs.
  
  
  CONCLUSIONS
  This study demonstrates the possibility of treating small, solid colon carcinoma tumors with α-emitting radionuclides such as 211At bound to mAbs, with tolerable toxicity.
authors.affiliation: Division of Oncology, Department of Clinical Sciences, Lund University, Barngatan 2B, Lund 221 85, Sweden. sophie.eriksson@med.lu.se.
authors.forename: Sophie E
authors.initials: SE
authors.lastname: Eriksson
authors.forename: Tom
authors.initials: T
authors.lastname: Bäck
authors.forename: Erika
authors.initials: E
authors.lastname: Elgström
authors.forename: Holger
authors.initials: H
authors.lastname: Jensen
authors.forename: Rune
authors.initials: R
authors.lastname: Nilsson
authors.forename: Sture
authors.initials: S
authors.lastname: Lindegren
authors.forename: Jan
authors.initials: J
authors.lastname: Tennvall
references.citation: Tumour Biol. 2012 Jun;33(3):573-90
references.pmid: 22143940
references.citation: Nucl Med Biol. 2001 Jan;28(1):33-9
references.pmid: 11182562
references.citation: Cancer Biother Radiopharm. 2007 Aug;22(4):480-7
references.pmid: 17803442
references.citation: J Nucl Med. 2005 Nov;46(11):1907-15
references.pmid: 16269606
references.citation: Eur J Cancer. 2010 May;46(7):1177-80
references.pmid: 20307970
references.citation: Br J Surg. 2005 Mar;92(3):264-76
references.pmid: 15739250
references.citation: Radiat Res. 2002 Jun;157(6):633-41
references.pmid: 12005541
references.citation: J Nucl Med. 2008 Sep;49(9):1537-45
references.pmid: 18703591
references.citation: Cancer Res. 2006 Aug 15;66(16):8227-32
references.pmid: 16912202
references.citation: Int J Radiat Oncol Biol Phys. 1996 Jan 1;34(1):251-66
references.pmid: 12118559
references.citation: Curr Mol Pharmacol. 2011 Jun;4(2):96-105
references.pmid: 21143185
references.citation: Curr Radiopharm. 2011 Oct;4(4):321-8
references.pmid: 22202154
references.citation: Eur J Nucl Med Mol Imaging. 2010 May;37(5):851-61
references.pmid: 20107790
references.citation: Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):572-9
references.pmid: 17869670
references.citation: Adv Drug Deliv Rev. 2008 Sep;60(12):1407-20
references.pmid: 18508155
references.citation: Cancer Biother Radiopharm. 2012 Mar;27(2):134-40
references.pmid: 22229635
references.citation: J Nucl Med. 2009 Jul;50(7):1153-60
references.pmid: 19525452
references.citation: Cancer Biother Radiopharm. 2009 Dec;24(6):649-58
references.pmid: 20025544
references.citation: Ann Surg. 2011 Feb;253(2):336-41
references.pmid: 21217519
references.citation: Lancet. 2010 Mar 20;375(9719):1030-47
references.pmid: 20304247
references.citation: Eur J Nucl Med Mol Imaging. 2011 Feb;38(2):271-3
references.pmid: 21161707
references.citation: Clin Cancer Res. 2011 Oct 15;17(20):6389-97
references.pmid: 22003066
references.citation: Cancer Res. 1990 Apr 1;50(7):2183-90
references.pmid: 1690595
references.citation: Phys Med Biol. 2007 Jul 7;52(13):L15-9
references.pmid: 17664565
references.citation: Clin Cancer Res. 2011 Oct 15;17(20):6406-16
references.pmid: 22003068
references.citation: Nucl Med Biol. 2009 Nov;36(8):883-94
references.pmid: 19875045
references.citation: J Clin Oncol. 2010 Oct 1;28(28):4390-9
references.pmid: 20697078
references.citation: J Oncol. 2010;2010:394913
references.pmid: 19859581
references.citation: Clin Cancer Res. 2008 May 1;14(9):2639-46
references.pmid: 18451227
references.citation: Cancer. 2010 Feb 15;116(4 Suppl):1043-52
references.pmid: 20127949
references.citation: J Nucl Med. 2005 Dec;46(12):2061-7
references.pmid: 16330571
references.citation: J Nucl Med. 2008 Jan;49(1):30-8
references.pmid: 18077533
references.citation: Nucl Med Biol. 1998 Apr;25(3):241-6
references.pmid: 9620629
references.citation: Ann Surg Oncol. 2007 Sep;14(9):2577-90
references.pmid: 17570017
references.citation: Ann Surg Oncol. 2009 Jul;16(7):2065-73
references.pmid: 19430843
references.citation: Med Phys. 2012 Jul;39(7):4434-43
references.pmid: 22830776
references.citation: J Nucl Med. 2013 Aug;54(8):1404-10
references.pmid: 23804328
references.citation: AAPS J. 2010 Mar;12(1):33-43
references.pmid: 19924542
references.citation: Trends Immunol. 2011 Nov;32(11):510-6
references.pmid: 21907000